Type II topoisomerases are ubiquitous enzymes that play an essential role in the control of replicative DNA synthesis and share structural and functional homology among different prokaryotic and eukaryotic organisms. Antibacterial fluoroquinolones target prokaryotic topoisomerases at concentrations 100-to 1000-fold lower than mammalian enzymes, the preferred targets of anticancer drugs such as etoposide. The mechanisms of action of both of these types of inhibitors involve the fixation of an intermediate reaction step, where the enzyme is covalently bound to an enzyme-mediated DNA double-strand break (DSB). The resulting ternary drug-enzyme-DNA complexes can then be converted to cleavage complexes that block further movement of the DNA replication fork, subsequently inducing stress responses. In haploid prokaryotic cells, stress responses include error-free and error-prone DNA damage repair pathways, such as homologous recombination and translesion synthesis, respectively. The latter can result in the acquisition of point mutations. Diploid mammalian cells are assumed to preferentially use recombination mechanisms for the repair of DSBs, an example of which, non-homologous end joining, is a major error-prone repair mechanism associated with an increased frequency of detectable small deletions, insertions and translocations. However, results obtained from safety testing of novel fluoroquinolones at high concentrations indicate that point mutations may also occur in mammalian cells. Recent data provide evidence for translesion synthesis catalysed by error-prone repair polymerases as a damage-tolerance repair mechanism of DSBs in eukaryotic cells. This paper discusses possible roles of different mechanisms for the repair of DSBs operating in both eukaryotic and prokaryotic cells that result in recombinational rearrangements, deletions/insertions as well as point mutations.
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Fluoroquinolones and topoisomerases
Fluoroquinolones are potent bactericidal drugs, the targets of which are the bacterial type II topoisomerases DNA gyrase and topoisomerase IV. They act by stabilizing the enzyme covalently bound to DNA in an intermediate drug-enzyme-DNA complex. The resulting ternary complex is then processed into a so-called cleavage complex, in which both 5#-phosphate ends of the broken DNA double strands (ds) are covalently attached via phosphotyrosine ester bonds to the respective A subunits of the bacterial A 2 B 2 heterodimeric topoisomerase (1) (2) (3) (4) .
Type II topoisomerases are ubiquitous enzymes (3, (5) (6) (7) (8) (9) (10) . Based on the amino acid sequence homology they can be subdivided into three separate, but related clusters, comprising bacterial topoisomerases II (DNA gyrases) and IV plus eukaryotic topoisomerase II enzymes (10) . Functionally, all type II enzymes exhibit multiple activities, including DNA binding, dsDNA cleavage and reunion displayed by prokaryotic subunits A as well as ATP hydrolysis by subunits B, whereas these activities are combined in each subunit of the homodimeric eukaryotic type II topoisomerases (6,7). In-vitro binding studies have revealed a common domain of interaction between eukaryotic topoisomerase II with both antineoplastic inhibitors, such as etoposide, amsacrin or genistein and fluoroquinolones (11) . Although the fluoroquinolone concentrations required in vitro to form a cleavage complex with native eukaryotic type II topoisomerase are 100-to 1000-fold higher than those required for gyrase (12) (13) (14) (15) (16) , site-directed mutagenesis of a few critical residues can increase the sensitivity of human topoisomerase II to fluoroquinolones (17) (18) (19) .
The mode of binding of fluoroquinolone molecules to a cleavage complex is non-covalent and reversible; thus, inhibitory fluoroquinolone concentrations are required to stabilize the DNA double-strand break (DSB) bridged by the topoisomerase. At subinhibitory concentrations, however, cleavage complex formation is reversible resulting in the restoration of the enzymatic activity and the completion of the religation reaction of the topoisomerase. Restoration of enzyme activity has been demonstrated, for example, in vivo after a component of the replication fork, such as the Escherichia coli helicase DnaB, collides with the cleavage complex (20) (21) (22) , or in vitro after addition of ethylendiaminetetraacetate (3, 23) .
In contrast, adding sodium dodecylsulfate and then proteinase K to a cleavage complex in vitro results in topoisomerase denaturation and then degradation, respectively. These linearized DNA fragments resulting from deproteinized DSBs carry tyrosine residues of the A subunits covalently bound to the 5#-phosphate ends and are released. Resulting linear DNA fragments can be separated electrophoretically from covalently closed circular dsDNA molecules (13) . The number of fluoroquinolone molecules bound to a single cleavage complex is believed to be stoichiometrically constant with two molecules per complex (4, 24) . Therefore, the proportion of ethidium bromide bound to a linear DNA topoisomer band, as measured by fluorescence, correlates quantitatively with the inhibitory activity of a quinolone on the topoisomerase (25, 26) .
Under in vivo conditions, the stability of a cleavage complex in a bacterial cell is affected by cellular responses that result in either removal or transient tolerance of the DSB. However, this tolerance may be at the expense of introducing mutations (repair pathways) (27, 28) or leading to cell death (bactericidal pathway). Immediate cell death following a fluoroquinoloneinduced interruption of DNA replication is observed due to irreversible DNA damage by hydroxyl radicals generated by the Fenton reaction (29) . Additionally, delayed cell death can occur as a consequence of persistent unrepaired DSBs (30, 31) .
DNA damage repair in response to quinolone action in bacteria
Nucleolytically active repair enzymes include the enzymes of the RecBCD complex, which are expressed as part of the SOS response. These enzymes exhibit a single-strand (ss) DNA exonuclease activity associated with the generation of free DNA ends (32) followed by endonucleolytic activities of the RuvABC complex (33) or the SbcCD complex of E. coli (34) . Free ssDNA ends resulting from these activities are bound by RecA molecules forming nucleoprotein filaments, which then activate the autoprotease activity of the LexA repressor. As a consequence, the complete SOS response (35) and probably other stress response systems (36) are induced. Among the SOS-controlled genes are sfiA, which encodes an inhibitor of cell division that may function to allow time for repair of the DNA damage, and recA, which encodes the key factor for strand pairing in homologous recombination (HR) reactions through activation of its ssDNA-invasion activity, which is involved in the formation of a transient triple helix (37) . Additionally, genes umuCD and dinB are activated to express low-fidelity DNA polymerase V (UmuD#2C), which plays a key role in SOS-mediated mutagenesis of bacteria by inducing the accumulation of replication errors in surviving cells (38, 39) , and DNA polymerase IV (DinB) (39) , which restarts DNA replication behind a DSB and repairs independently from other DNA polymerases (21) . The latter is called translesion synthesis (TLS), which allows DNA replication to bypass a DSB, preferentially at the expense of inducing singlenucleotide exchanges or single-base deletions (40) . Cells may benefit from this enhanced mutational activity by ensuring long-term survival as well as evolutionary fitness (41), e.g. if such mutations affect the expression of virulence factors or the development of antibiotic resistance (42) . Recent findings indicate that in the absence of an induced SOS response, the development of fluoroquinolone resistance is even impaired (43) . Thus, the error-prone activities of the SOS response are considered to be part of an intrinsic system of adaptive bacterial response to DNA damaging stress in those cells that have not been killed by the antibiotic (43, 44) .
Beside the SOS response, which preferentially repairs DSBs via error-free HR or tolerates them via error-prone TLS, alternative pathways resulting in large chromosomal rearrangements have been described. These are thought to predominate in eukaryotic cells and include illegitimate recombination and non-homologous end joining (NHEJ). The former is accomplished by subunit exchange between two type II topoisomerase holoenzymes bound in two separate cleavage complexes, which results in the ligation of DNA ends from the two separate DSBs (44). NHEJ is a major repair pathway in resting mammalian cells (45) and has also been reported in mycobacteria as an alternative repair pathway for DSBs by religating modified DNA ends (46) . In the event that no second copy of the chromosomal DNA is available, NHEJ is the only mechanism by which resting bacteria can repair DSBs, albeit at the expense of introducing mutations.
In summary, fluoroquinolones inhibit DNA replication by trapping DNA gyrase in a DNA-bound state thereby inducing irreversible oxidative DNA damage that can kill bacterial cells. Some cells can survive by responding through either error-free (HR) or error-prone DNA repair mechanisms. Error-prone mechanisms include illegitimate recombination, NHEJ and RecABCD-directed repair, which result in large rearrangements, small insertions/deletions and single-nucleotide exchanges, respectively. The latter can be detected with the Salmonella Ames test as an intrinsic feature of the molecular mode of action of all quinolones (28) .
Fluoroquinolones and mammalian topoisomerases
The structural and functional homology between the different type II topoisomerases is the molecular basis for the conserved mode of interaction between enzyme and DNA, and also serves as a common cellular response mechanism to drug action, i.e. DSB formation and cytotoxic/bactericidal effects. However, due to the differences in chromosome structure between bacterial (haploid) and mammalian (diploid) cells, the mechanisms involved in the repair of DNA DSBs are expected to differ, as well as the types of mutations resulting from imperfect repair mechanisms.
In vertebrate cells, type II topoisomerases exist in two isoforms, a and b (6,7). Isoform b seems to be non-essential and shows a higher susceptibility to 26S proteasome-mediated degradation in cleavage complexes (47) , whereas isoform IIa is essential and is highly expressed in actively replicating mammalian cells where it is associated with replication forks (48) . Inhibitors bind to topoisomerase IIa by forming non-covalent and reversible cleavage complexes, both in vivo and in vitro (15, 16) . Lowering the inhibitor concentration results in diffusion of the drug and religation of the enzyme-stabilized DSB, whereas maintaining inhibitory drug concentrations stabilizes cleavage complexes (49), thereby inducing a cascade of events by subsequent cellular responses. These include genotoxic and mutagenic effects resulting from error-prone DNA damage repair and are thought to be associated with secondary malignancies resulting from etoposide therapy. In addition, cytotoxic responses may also occur as a result of the induction of apoptosis resulting in chromosome fragmentation [summarized in (50) ].
A key step in converting a reversible cleavage complex containing mammalian topoisomerases into a stabilized cleavage complex is thought to be the collision with the replication fork, which subsequently is stalled (51) . This stalling induces different cellular responses depending upon the state of the cell cycle, which can be arrested at the G1/S and the G2/M transition, or slowed down in S-phase to allow time for repair of DNA damage (52) .
DNA damage repair in mammalian cells
The molecular mechanisms inducing DNA damage repair pathways in mammalian cells are not yet fully understood. However, one key player is the ser/thr kinase ATM, which is activated by etoposide-induced DSBs and is detectable by rapid phosphorylation of different substrates including histone H2AX and p53. Additionally, an endo and exonucleolytically active complex, MRN, is involved in DSB signalling and DNA end-positioning for subsequent homologous recombination repair (53) . Monitoring histone c-H2AX phosphorylation can be used as an early and sensitive marker of DSBs in eukaryotic cells (54) . Other assays for genotoxicity detect events resulting from DSBs, such as the formation of micronuclei in TK6 lymphoblastoid cells (55) , chromosomal fragmentation resulting from multiple DSBs detectable by pulsed-field gel electrophoresis (56) or after alkaline denaturation of single cells embedded in an agarose matrix and electrophoresis by the comet assay (57) .
Several enzymes involved in DNA damage repair are conserved among prokaryotic and eukaryotic cells (58) , although the eukaryotic repertoire of responses to DSBs is more broad. These responses include different error-free mechanisms such as HR and synthesis-dependent strand annealing, and potentially error-prone mechanisms, such as NHEJ, break-induced replication, which can lead to gene conversion, and single-strand annealing (59) . The presence of a diploid genome in eukaryotes suggests a preference for recombinational repair mechanisms, such as NHEJ, which is the major error-prone repair pathway of DSBs in human cells (60) . NHEJ results in small chromosomal rearrangements (insertions, deletions) (61) and is mediated by several repair enzymes including specific DNA end-binding proteins, such as Ku (comprising Ku80 and Ku86), ligase IV (combining polymerase/ligase activities) and DNA-PKc (a DNA-dependent kinase) (62) . Following the binding of a Ku monomer to each DNA end and dimerization of the two Ku proteins, the DNA ends are assembled in close proximity as required for the subsequent ligation reaction catalysed by ligase IV (61) . The religation of broken ends usually results in small insertions at the joining site due to degradation of short single-strand overlaps, or filling in of gaps by nuclease or polymerase activities, respectively. In the case of blunt-ended breaks, a single base pair is inserted (63) .
Fluoroquinolone action on mammalian cells
The detection of single-nucleotide exchanges (point mutations) in the hprt gene of V79 cells after treatment with fluoroquinolone could be regarded as atypical of fluoroquinolones, and not due to topoisomerase inhibition (14) .
Recent progress in understanding the biological role and the molecular basis for bypass repair mechanisms of DSBs in eukaryotic cells provides a plausible explanation for these positive results from hypoxanthine-guanine phosphoribosyltransferase (HPRT) assays (64) . Experiments using chemical (e.g. psoralen, mitomycin, cis-platin) or physical (UV light) mutagens to block DNA replication, resulting in the formation of DSBs and induction of DNA repair activities, have provided evidence for a role of TLS by error-prone DNA polymerases as an efficient and rapid repair mechanism (65) . The first evidence for such a mechanism, which bypasses the DSB and restarts the DNA replication fork behind the block, comes from studies in yeast cells (65) . More recent findings indicate a comparable role of these enzymes in humans where at least 10 such enzymes have been detected (66) . The biological role and the mechanisms of action of such TLS polymerases, which include human DNA polymerases homologous to yeast polymerases eta, zeta and iota, resemble those of bacterial Pol IV and Pol V, which are induced by the SOS repair system in prokaryotes (67) . Mechanistically, these DNA polymerases are able to insert mismatches opposite to, e.g. a pyrimidine dimer (due to a UV light-induced block of the replication fork) and reinitiate the synthesis of a short DNA stretch on the lagging as well as on the leading strand resulting in the occurrence of point mutations (68) .
Conclusion
Although it has not been shown experimentally, it is plausible that a quinolone-mediated arrest of the replication fork movement induces error-prone TLS repair analogous to other inducers of DSBs via mono-ubiquitinylation of proliferating cell nuclear antigen as one common response to replication fork arrest (52) . This, in turn, could give rise to singlenucleotide exchanges. Investigations on the biological role of TLS repair may highlight the importance of this error-prone repair system for the survival of cells in the presence of cytotoxic agents (69) . Thus, the detection of single-nucleotide alterations in the HPRT assay in the presence of very high concentrations of fluoroquinolones can plausibly be explained by the activity of such error-prone repair mechanisms, which can be regarded as part of the cellular response to topoisomerase inhibitors. Moreover, since these ubiquitous mechanisms also play a vital role in maintaining a certain level of genetic variation for fundamental biological processes, like immunoglobulin gene diversification (70) , they need to be considered when interpreting genotoxicity studies involving topoisomerase inhibitors, such as fluoroquinolones.
